Cardiac Registries During the COVID-19 Pandemic: Lessons Learned

Abstract

Purpose of this Review We discuss the role of observational studies and cardiac registries during the COVID-19 pandemic. We focus on published cardiac registries and highlight contributions to the field that have had clinical implications. Recent Findings We included observational studies of COVID-19 patients published in peer-reviewed medical journals with defined inclusion and exclusion criteria, defined study design, and primary outcomes. A PubMed and MEDLINE literature review results in 437 articles, of which 52 include patients with COVID-19 with cardiac endpoints. From July 2020 to December 2021, the average time from last data collected to publication was 8.9 ± 4.1 months, with an increasing trend over time ( R = 0.9444, p < 0.0001). Of the 52 articles that met our inclusion criteria, we summarize main findings of 4 manuscripts on stroke, 14 on acute coronary syndrome, 4 on cardiac arrest, 7 on heart failure, 7 on venous thromboembolism, 5 on dysrhythmia, and 11 on different populations at risk for cardiovascular. Summary Registries are cost effective, not disruptive to essential health services, and can be rapidly disseminated with short intervals between last data point collected and publication. In less than 2 years, cardiac registries have filled important gaps in knowledge and informed the care of COVID-19 patients with cardiovascular conditions. Supplementary Information The online version contains supplementary material available at 10.1007/s11886-022-01686-5.

Cardiovascular Factors Associated with COVID-19 from an International Registry of Primarily Japanese Patients

“…By March 2020, the infection had spread around the world and was declared to be a pandemic [ 1 ]. Early in the pandemic, a number of international registries were developed to examine cardiovascular outcomes from COVID-19 including the American Heart Association (AHA) COVID-19 Cardiovascular Disease (CVD) registry, the International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease (PCHF-COVICAV) registry (15 countries) and the Lean European Open Survey on SARS-CoV-2 (LEOSS) Registry [ 4 , 5 , 6 ]. In March 2020 we also developed an international registry at Mayo Clinic in collaboration with the International Society of Cardiomyopathy, Myocarditis and Heart Failure (ISCMF) to examine cardiovascular outcomes from COVID-19 with an emphasis on unrecognized myocarditis.…”